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ABSTRACT
Researchers have attempted to use gene- and cell-based therapies to restore dystrophin and alleviate the mus-
cle weakness that results from Duchenne muscular dystrophy (DMD). Our research group has isolated pop-
ulations of muscle-derived stem cells (MDSCs) from the postnatal skeletal muscle of mice. In comparison with
satellite cells, MDSCs display an improved transplantation capacity in dystrophic mdx muscle that we at-
tribute to their ability to undergo long-term proliferation, self-renewal, and multipotent differentiation, in-
cluding differentiation toward endothelial and neuronal lineages. Here we tested whether the use of nerve
growth factor (NGF) improves the transplantation efficiency of MDSCs. We used two methods of in vitro NGF
stimulation: retroviral transduction of MDSCs with a CL-NGF vector and direct stimulation of MDSCs with
NGF protein. Neither method of NGF treatment changed the marker profile or proliferation behavior of the
MDSCs, but direct stimulation with NGF protein significantly reduced the in vitro differentiation ability of
the cells. NGF stimulation also significantly enhanced the engraftment efficiency of MDSCs transplanted within
the dystrophic muscle of mdx mice, resulting in the regeneration of numerous dystrophin-positive muscle
fibers. These findings highlight the importance of NGF as a modulatory molecule, the study of which will




Growth factors play important roles as signaling molecules
throughout postnatal development, adult life, and aging. This
study investigated the effect of nerve growth factor (NGF) on
the regeneration of the skeletal muscle of dystrophic (mdx)
mice. Transplantation of muscle-derived stem cells (MDSCs)
either stimulated with or genetically engineered to express
NGF resulted in the regeneration of significantly more dys-
trophin-positive myofibers than did transplantation of con-
trol (nontreated) MDSCs. NGF did not alter the marker pro-
file or proliferation behavior of MDSCs; however, MDSCs
stimulated with NGF exhibited reduced in vitro differentia-
tion, which may at least partially explain their improved re-
generation capacity. These findings underscore the impor-
tance of NGF during skeletal muscle tissue remodeling and
indicate that this molecule can improve the muscle regener-
ation capacity of muscle stem cells.
INTRODUCTION
DUCHENNE MUSCULAR DYSTROPHY (DMD) is a progressivemuscle disorder characterized by dystrophin deficiency
that results in initial necrosis of muscle fibers, which in turn
leads to progressive muscle weakness (Duchenne, 1868; Hoff-
man et al., 1987a; Gorospe and Hoffman, 1992). Researchers
have localized dystrophin in the sarcolemma of myofibers (Ara-
hata et al., 1988; Bonilla et al., 1988; Watkins et al., 1988),
where it is thought to play a role in maintaining plasma mem-
brane integrity and stability (Hutter et al., 1991; Menke and
Jockusch, 1991; Petrof et al., 1993). Because dystrophic mus-
cle has a heightened susceptibility to structural damage and a
decreased capacity to undergo self-repair, early death com-
monly occurs as a result of congestive cardiac and/or respira-
tory failure.
Despite the extensive efforts of researchers to develop an ef-
fective way to deliver dystrophin in dystrophic muscle (e.g.,
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cell and gene therapy), there is no known treatment that sub-
stantially slows the course of DMD and rescues the diseased
muscle tissue. Because of the unavailability of successful gene
therapy, researchers have attempted to use a variety of other
approaches to impede the predictable, progressive decline in
muscle strength; the most successful of these approaches in-
volves the use of steroids. Several randomized trials focused on
corticosteroids (mainly prednisone and deflazacort) have shown
that steroids improve muscle function and strength by pro-
longing ambulation and preventing scoliosis in boys with DMD
(Biggar et al., 2004; Bushby et al., 2004; Yilmaz et al., 2004).
Although the mechanism is not clear, corticosteroids have 
antiinflammatory and membrane-stabilizing effects (Alman,
2005) and act as catabolic agents, reducing muscle fiber size in
the skeletal muscle of mdx mice and making the fibers less sus-
ceptible to contraction-induced muscle damage (Lynch et al.,
2000). However, because not all clinical trials have generated
conclusive results showing the efficacy and safety of long-term
steroid use, the utility of these drugs remains unknown (Lynch,
2001; Campbell and Jacob, 2003; Manzur et al., 2004).
Advances in clinical management also have significantly im-
proved the life expectancy of DMD patients, their functional
ability, and their quality of life. These advances include the use
of respiratory muscle training, noninvasive ventilation (Smith
et al., 1988; Bach et al., 1991), a mechanical in-exsufflator for
pediatric patients (Miske et al., 2004), and low-resistance ex-
ercise and voluntary active exercises such as swimming and hy-
drotherapy, which increase muscle strength and endurance (for
review, see Eagle, 2002). In addition, physical therapy can help
relax joint contractures and early stabilization of the spine can
maintain patient balance and slow the progression of respira-
tory compromise (Harper et al., 2004).
Like the muscles of humans with DMD, the muscles of mdx
mice are dystrophin deficient because of a point mutation in the
dystrophin gene (Hoffman et al., 1987b); this genetic similar-
ity makes the mdx mouse an excellent genetic and biochemical
model for DMD. Unlike the muscles of humans with DMD,
however, the muscles of mdx mice maintain active and efficient
regeneration that compensates for the repeated cycles of de-
generation. Although the limb skeletal muscle of mdx mice con-
tinues to undergo relatively efficient regeneration regardless of
the age of the animals, muscles in the diaphragms of mdx mice
of all ages and in the postural-tonic muscles (such as the soleus)
of old mice (more than 52 weeks) exhibit many pathologic fea-
tures identical to those observed in the muscle of DMD patients,
including fiber atrophy; frequent splitting, necrosis, and pro-
gressive fibrosis; and severe loss of tissue compliance (Sted-
man et al., 1991; Pastoret and Sebille, 1993, 1995).
Although lack of dystrophin leads to progressive muscle de-
generation, the evolution of DMD is likely dependent on other
factors, such as insufficient expression of growth-associated
proteins. After skeletal muscle damage, quiescent myogenic
stem cells, which are normally embedded in the basal lamina
of the muscle fibers, are activated; these cells migrate toward
the damaged area, where they undergo a cycle of proliferation,
fusion, and differentiation that culminates in the generation of
myofibers that replace the damaged ones (Grounds, 1991). Var-
ious growth factors appear to regulate skeletal myoblast prolif-
eration and differentiation, play a role in different stages of mus-
cle regeneration, and enhance the healing process (Allen et al.,
1990; Florini et al., 1991; Trippel, 1997). In addition to stim-
ulating cell proliferation, growth factors can support cell sur-
vival and regulate critical intracellular signal transduction path-
ways (Weiss and Schlessinger, 1998) under conditions that
otherwise lead to apoptotic death.
To date, the list of growth factors known to affect the be-
havior of skeletal muscle cells or be expressed in skeletal mus-
cle tissue is extensive. However, few studies have investigated
the role of nerve growth factor (NGF) during skeletal muscle
regeneration, and its exact mechanism of action is poorly un-
derstood. In addition to acting as a target-derived factor for de-
veloping neurons, NGF has an autocrine effect on myoblast pro-
liferation and fusion (Rende, 1998; Ou et al., 1999; Rende et
al., 2000). Moreover, adult knockout mice expressing a neu-
tralizing antibody against NGF display a severe dystrophy and
reduced muscle mass (Capsoni et al., 2000; Ruberti et al.,
2000). Evidence suggests that NGF acts by binding to the high-
affinity tyrosine kinase receptor (TrkA) and the low-affinity
p75-neurotrophin receptor (p75NTR). TrkA is found in devel-
oping adult rat myoblasts (Wheeler et al., 1998) and during dif-
ferentiation of muscle cells (Rende et al., 2000). NGF and
p75NTR are widely expressed in myoblasts, human myocyte cul-
tures, and regenerating myofibers in the muscle of DMD pa-
tients (Zhao et al., 1991; Baron et al., 1994).
Previous studies in our laboratory have revealed that the de-
livery of human recombinant NGF protein by direct intramus-
cular injection improves muscle recovery (Kasemkijwattana et
al., 2000; Menetrey et al., 2000). However, the efficiency of
direct intramuscular injection of growth factors varies depend-
ing on the type of injury encountered and is limited by the need
to maintain high-enough concentrations to achieve a therapeu-
tic effect. In addition, the use of growth factor proteins to pro-
mote healing is severely hindered by the difficulty of ensuring
their delivery to the injured site (Evans and Robbins, 1994),
their short biologic half-lives (Evans and Robbins, 1994; Rob-
bins and Ghivizzani, 1998), and the rapid clearance of these
molecules from the bloodstream. For the study reported here,
we used a combination of muscle-derived stem cell (MDSC)-
based gene therapy and direct stimulation with NGF protein to
examine the effects of NGF on the proliferation and differen-
tiation capacity of MDSCs in vitro and their regeneration effi-
ciency in mdx muscle in vivo.
MATERIALS AND METHODS
Animals
mdx mice (C57BL/10SCsn DMDmdx/J) were purchased from
the Jackson Laboratory (Bar Harbor, ME). All animal proto-
cols used for these experiments were approved by the Institu-
tional Animal Care and Use Committee of Children’s Hospital
of Pittsburgh (protocol 3/02).
Cell isolation and culturing
A previously described modified preplate technique (Qu-Pe-
tersen et al., 2002) was used to obtain MDSCs from normal
(C57BL/6J) 3-week-old female mice. Cells were cultured at an
initial density of 450 cells/cm2 in flasks coated with collagen
type I (Sigma-Aldrich, St. Louis, MO) and were maintained in
proliferation medium (Dulbecco’s modified Eagle’s medium
[DMEM] supplemented with 10% horse serum, 10% fetal
bovine serum [FBS], and 1% penicillin–streptomycin; all
GIBCO-brand reagents from Invitrogen, Carlsbad, CA) con-
taining 0.5% chick embryo extract (Accurate Chemical, West-
bury, NY). After 2 days of growth (confluency  50%), the
cells were trypsinized, counted, and replated to generate the
quantity of cells needed for each experiment.
Generation of retroviral vector expressing NGF
NGF cDNA was amplified from plasmid pSP72NGFpA
(kindly provided by P. Robbins, University of Pittsburgh, Pitts-
burgh, PA) with primers NGF1 (agg cgg ccg ccc acc atg ctg
tgc ctc aag cca gtg aaa) and NGF2 (tca aga tct tca gcc tct tct
tgt agc ctt cct) and Pfu DNA polymerase (Stratagene, La Jolla,
CA). The polymerase chain reaction (PCR) product was cut
with restriction enzymes NotI and BglII and cloned into the
same two sites of retroviral vector pCLX. The vector DNA was
converted into a replication-defective retrovirus by cotransfec-
tion (by calcium phosphate precipitation) into packaging cell
line GP-293 (Clontech, Palo Alto, CA) with a plasmid, pVSVG,
that expressed vesicular stomatitis virus glycoprotein as the vi-
ral envelope (Peng et al., 2002). Conditioned medium contain-
ing retroviral vector was stored at 80°C until use.
Stimulation or retroviral transduction of MDSCs 
with NGF
MDSCs were plated at 20–30% initial confluency and either
stimulated with NGF (100 ng/ml; Sigma-Aldrich) for 7 days
(S-MDSCs) or retrovirally transduced (in the presence of Poly-
brene [8 g/ml]) with the CL-NGF vector to express NGF (E-
MDSCs) at a multiplicity of infection of 5. Normal MDSCs nei-
ther stimulated nor transduced served as the control group
(C-MDSCs). E-, S-, and C-MDSCs were expanded for 1 week
in proliferation medium (20% serum) at an initial density of
8  104 cells per well on collagen type I-coated 6-well plates,
where they remained for 48 hr; the proliferation medium then
was replaced with low-serum medium (2% FBS), in which the
cells were cultured for an additional 24 hr. Tissue culture su-
pernatant was collected and spun at 1200 rpm for 5 min at 4°C,
and the level of functional NGF secreted by the cells in the tis-
sue culture supernatant was measured by enzyme-linked im-
munosorbent assay (ELISA) (NGF Emax ImmunoAssay System
kit; Promega, Madison, WI) performed as detailed in the man-
ufacturer’s instructions.
Cell characterization by flow cytometry
Flow cytometry was used to analyze the expression of the
cell surface markers CD34 and stem cell antigen-1 (Sca-1). Cul-
tured cells were trypsinized, spun, washed in a buffer solution
made of phosphate-buffered saline (PBS) (Dulbecco phosphate-
buffer salt solution 1; Mediatech, Herndon, VA) containing
0.5% bovine serum albumin (BSA; MP Biomedicals, Irvine,
CA) and 0.1% sodium azide (Sigma-Aldrich), and counted. Af-
ter trypsinization, the cells were maintained on ice for the re-
mainder of the procedure. The cells were then divided into ali-
quots and spun into a pellet. A blocking solution containing a
1:10 dilution of mouse serum (Sigma-Aldrich) in the buffer so-
lution described above supplemented with 1 l of Fc block (rat
anti-mouse CD16/CD32; BD Biosciences Pharmingen, San
Diego, CA) was used to resuspend each pellet, and the sus-
pensions were incubated for 10 min on ice. Predetermined, op-
timal amounts of both direct and biotin-conjugated rat anti-
mouse monoclonal antibodies (CD34 and Sca-1) were each
placed in tubes for 30 min. Each experimental tube received
fluorescein isothiocyanate (FITC)-conjugated CD34 and biotin-
conjugated Sca-1. A separate cell portion received equivalent
amounts of isotype control antibodies. After several rinses, all
fractions (including the controls) were labeled with strepta-
vidin–allophycocyanin (APC) for 20 min. Just before analysis,
7-amino-actinomycin D (7-AAD) was added to each tube to ex-
clude nonviable cells from the analysis. All antibodies, includ-
ing APC and 7-AAD, were purchased from BD Biosciences
Pharmingen. At least 10,000 live cell events were analyzed by
flow cytometry (FACSAria cytometer using FACSDiva soft-
ware; BD Biosciences Immunocytometry Systems, Mountain
View, CA).
Myogenic marker expression analyzed by
immunocytochemistry
A fraction of each cell group was evaluated by immunoflu-
orescence staining for expression of the myogenic proteins
desmin and Pax-7. Analysis was performed on methanol-fixed
cells that were blocked with 5% goat serum in PBS for 1 hr.
The cells were incubated for 1 hr with the following primary
antibodies: mouse IgG anti-desmin (diluted 1:250; Sigma-
Aldrich) and mouse anti-Pax-7 (diluted 1:50; R&D Systems,
Minneapolis, MN). After being rinsed thoroughly with PBS, the
cells were incubated for 30 min with the secondary antibody,
biotinylated goat anti-mouse IgG (diluted 1:250; Vector,
Burlingame, CA). To fluorescently label the antigenic binding,
the cells were washed and incubated with streptavidin–Cy3 (di-
luted 1:500; Sigma-Aldrich) for 10 min; nuclei then were coun-
terstained with 4,6-diamidino-2-phenylindole (DAPI, diluted
1:104; Sigma-Aldrich) in PBS. All dilutions were in 5% goat
serum in PBS at room temperature. Negative control staining
was performed according to an identical procedure, with omis-
sion of the primary antibody. Northern Eclipse software (ver-
sion 6.0; EMPIX Imaging, Mississauga, ON, Canada) was used
to quantify the percentage of myogenic cells as the ratio of cells
that strongly expressed desmin or Pax-7 to the total number of
nuclei in 10 randomly chosen fields at 200 magnification.
Cell division and myogenic differentiation
For analyses of population doubling time (PDT) and cellu-
lar division time (DT), cells from each group were plated at an
initial density of 500 cells per well in a collagen type I-coated
12-well plate. A novel microscope imaging system (Cyto-
Works; Automated Cell, Pittsburgh, PA) equipped with a 20
objective was used to acquire images at 10-min intervals over
a period of 4 days. DT was measured for each treatment con-
dition by selecting and tracking 100 cells directly from a time-
lapsed video record; the time lapse between cytokinesis events
was recorded as the length of the cell division cycle. The av-
erage PDT was calculated by fitting an exponential trend line
to several measured data points. PDT was estimated by using
the software package SigmaStat 2.0 (SPSS, Chicago, IL) to per-
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form nonlinear regression to generate the best fit to the curve.
The fraction of daughter cells that were dividing () was cal-
culated by measuring PDT and DT and solving the rearranged
Sherley model to obtain the correlation coefficient (R2) for the
nonlinear regression (Sherley et al., 1995; Deasy et al., 2002),
a value that indicates how well the data actually fit the model
(such that 0  R2  1.0).
Myogenic differentiation was evaluated by immunocyto-
chemical staining for MyoD and fast myosin heavy chain
(MyHC) expression. MyoD is a marker of early myogenic dif-
ferentiation, whereas MyHC is a marker of terminal myogenic
differentiation. E-, S-, and C-MDSCs were plated in collagen
type I-coated 24-well plates in high-serum DMEM (described
earlier). To induce differentiation, proliferation medium was re-
placed with differentiation medium (low serum: DMEM supple-
mented with 2% FBS and 1% penicillin–streptomycin). Two sets
of experiments were performed to permit assessment of the rate
of differentiation at multiple time points. In the first set of ex-
periments, cells from each group were seeded at a density of 500
cells/cm2. The cultures were shifted into differentiation medium
after 3 days, and the cells were stained for MyoD and MyHC at
2, 4, 6, and 8 days. In the second set of experiments, cells from
each group were seeded at a density of 1000 cells/cm2. The cul-
tures were shifted into differentiation medium 1 day after seed-
ing, and the cells were stained for MyoD and MyHC at 3, 5, 7,
9, and 11 days. The differentiation medium was replaced every
2 days. Immunocytochemistry staining for MyHC was performed
as described earlier for myogenic markers with monoclonal
mouse anti-MyHC (diluted 1:250; Sigma-Aldrich) as the primary
antibody. For immunofluorescence staining of MyoD, cultured
cells were fixed with 2% paraformaldehyde in PBS containing
1% Triton X-100 and were blocked in 5% horse serum in PBS
for 1 hr. The cells then were incubated for 3 hr with anti-MyoD
monoclonal antibody clone 5.8A (diluted 1:150; BD Biosciences
Pharmingen) in the same blocking solution. The cells were ex-
posed to a secondary biotinylated anti-mouse IgG (diluted 1:200;
Vector Laboratories, Burlingame, CA) in PBS for 1 hr and to
streptavidin–Cy3 (diluted 1:500; Sigma-Aldrich) for 15 min. Nu-
clei were counterstained with DAPI. All procedures were per-
formed at room temperature. Negative control staining was per-
formed by an identical procedure, but the primary antibody was
omitted. For each group and time point, 10 randomly chosen rep-
resentative fields were evaluated at 200 magnification to de-
termine the degree of differentiation (percent ratio of MyoD- or
MyHC-expressing nuclei to total number of nuclei), an indicator
of differentiation efficiency.
Myofiber regeneration in vivo
A total of (2–3)  105 C-, E-, or S-MDSCs was injected
into the gastrocnemius muscle of 6- to 8-week-old male mdx
mice. Mice in the E-MDSC group and their controls were im-
munosuppressed by subcutaneous injection of tacrolimus
(C44H69NO12  H2O), previously known as FK506 (2.5 mg/kg
mouse body weight per day; Astellas Pharma US, Deerfield, IL)
beginning on the day of cell transplantation and continuing until
the day of euthanization; this immunosuppression protocol is de-
scribed elsewhere (Kinoshita et al., 1994). Ten to 14 days after
transplantation, the gastrocnemius muscles were harvested, flash
frozen in liquid nitrogen-cooled 2-methylbutane, and serially sec-
tioned (10 m). For dystrophin staining of the cryopreserved tis-
sue, acetone-fixed, horse serum-blocked sections were exposed to
a rabbit anti-dystrophin antibody (diluted 1:1000, kindly provided
by T. Partridge, Imperial College of Medicine, London, UK) for
3 hr, as previously described (Lu et al., 2003). Sections then were
washed in PBS and incubated with biotinylated anti-rabbit IgG
antibody for 1 hr. Next, the sections were washed again and in-
cubated with streptavidin–Cy3 (diluted 1:300; Sigma-Aldrich) for
FIG. 1. Schematic of the retroviral vector expressing NGF. The vector CL-NGF carries a 3 long terminal repeat (LTR), virus
packing signal (), and human NGF cDNA driven by the cytomegalovirus promoter (CMV-P).
FIG. 2. Quantitative detection of the NGF
protein in cell supernatant by ELISA. Two dif-
ferent methods of NGF stimulation were used
in this study: retroviral transduction of MD-
SCs with the CL-NGF vector to induce ex-
pression of human NGF (E-MDSCs) and di-
rect stimulation of MDSCs with NGF protein
(100 ng/ml) for 7 days (S-MDSCs). For both
groups, normal MDSCs that were neither stim-
ulated nor transduced served as controls (C-
MDSCs). ELISA results revealed that, in com-
parison with S- and C-MDSCs, E-MDSCs
produced a significantly higher level of NGF
3, 6, and 9 days after transduction (n  3, *p 
0.05).
20 min. All incubations were at room temperature. Fluorescence
microscopy was performed and digital images were acquired with
a Nikon Eclipse E800 microscope equipped with a Spot digital
camera and Northern Eclipse software (version 6.0; EMPIX Imag-
ing). Muscle regeneration was assessed by manually counting the
number of dystrophin-positive myofibers in an area containing the
largest graft and calculating the regeneration efficiency index (RI:
the number of dystrophin-positive fibers in the host muscle per
105 donor cells) for ease of both comparison and graphical dis-
play (Jankowski et al., 2002).
Myofiber analysis
Northern Eclipse software and the same images used to cal-
culate the RI were used to perform dimensional analysis of re-
generated dystrophin-positive myofibers. Using a threshold to
distinguish the immunofluorescence signal from the back-
ground signal, this software determines the area of each fiber
and provides quantitative measurements of the number of pix-
els occupied by each individual fiber. The fiber area distribu-
tion (FAD) of 4000 individual myofibers per group was mea-
sured by determining the total number of pixels occupied by
each fiber—a number that was easy to convert to square mi-
crometers with analysis software. Hematoxylin and eosin
(H&E) staining of noninjected regions of the same grafts was
used to detect the boundaries of the host mdx myofibers.
Statistical analysis
Differences with p  0.05 were considered statistically sig-
nificant. All values are given as the mean  standard deviation
of the mean (SD). The Student t test or the Mann–Whitney rank
sum test (where appropriate) was used for direct comparisons
between treatment and control groups. Multiple group compar-
isons were made through the use of one-way analysis of vari-
ance (ANOVA) and Student–Newman–Keuls pairwise com-
parisons to determine the significance level. Nonparametric dis-
tributions were also detected, and comparisons were made using
Kruskal–Wallis one-way ANOVA on ranks with the Tukey test
for pairwise comparisons or the Dunnett test for comparing
treatment groups with a single control group.
RESULTS
Quantitative detection of NGF
We used an ELISA to measure the levels of NGF secreted
by MDSCs in vitro. After transduction with retroviral NGF
(schematic shown in Fig. 1), genetically engineered MDSCs (E-
MDSCs) were able to synthesize, process, and secrete active
human NGF. The level of NGF secreted by E-MDSCs reached
307.4  42.5 ng/106 cells per 24 hr 3 days after transduction
and continued to be high 6 and 9 days after transduction
(173.2  11.1 and 164.9  28.2 ng/106 cells per 24 hr, re-
spectively, n  3, p  0.05). In contrast, NGF-stimulated MD-
SCs (S-MDSCs) and control (nontreated) MDSCs (C-MDSCs)
on average secreted NGF at barely detectable levels at the three
time points (0.09  0.17 and 0.02  0.37 ng/106 cells per 24
hr, averages for S-MDSCs and C-MDSCs, respectively; Fig. 2).
Proliferation kinetics
To investigate the cellular response of MDSCs to NGF, we
examined cellular division time (DT) and population doubling
time (PDT). Using images acquired every 10 min for a period of
4 days, we measured the DT of the dividing cells (n  100 cells
per group) by recording the lapsed time between cytokinesis
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FIG. 3. Proliferation kinetics of MDSCs. Shown is the independent variable, time (t), versus the dependent variable, normal-
ized cell number. Comparison of the C-, E- , and S-MDSC groups (n  100 cells per group, p  0.053) revealed no differences
in the average cellular division time (DT) or population doubling time (PDT). We fit the experimental data sets to the model
equations by using nonlinear regression to estimate the mitotic fraction () (i.e., the fraction of daughter cells that was actively
dividing). The mean mitotic fraction remained relatively constant among the groups (approximately 0.94).
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events. We fit experimental data sets for C-, E-, and S-MDSCs
to the Sherley model equations by using nonlinear regression with
the correlation coefficient R2  0.90 to estimate mitotic fraction
() (i.e., the fraction of daughter cells that are actively dividing).
Our data suggest that the average DTs (C-MDSCs, 11.9 hr; E-
MDSCs, 11.5 hr; and S-MDSCs, 12.1 hr) were not significantly
different in the various groups (p  0.053, Kruskal–Wallis anal-
ysis on ranks) and that the PDTs of the different cell groups were
also quite similar (11–13 hr). Moreover, we observed a strong
association for the three groups (as indicated by R2  0.99) but
no difference in the estimated  (C-MDSCs, 0.95; E-MDSCs,
0.94; S-MDSCs, 0.92) (Fig. 3). These results indicate that nei-
ther NGF transduction nor NGF stimulation significantly altered
the proliferation kinetics of MDSCs.
In vitro stem cell and myogenic marker 
expression profiles
Flow cytometry revealed similar expression of CD34 and 
Sca-1 by C-, E-, and S-MDSCs (Fig. 4A). More than 70% of the
cells in each group were positive for both stem cell markers, and
we observed no significant difference between the groups (in terms
of stem cell marker expression) after 2 weeks of in vitro expan-
sion (n  3, p  0.655). This marker stability suggests that NGF
did not affect the stem cell marker expression of MDSCs in vitro.
We also used immunofluorescence staining to assess ex-
pression by the cells of two myogenic proteins: Pax-7 and
desmin. As shown in Fig. 4B, there was no significant dif-
ference in the expression of Pax-7 by the various groups of
treated and nontreated MDSCs (n  4, p  0.148). Whereas
E- and C-MDSCs expressed similar levels of desmin, the S-
MDSC group contained significantly more desmin-expressing
cells (n  4, p  0.05).
In vitro myogenic differentiation
After cultivating the cells under low-serum conditions and at
various densities, we performed immunohistochemical staining
for MyoD and fast myosin heavy chain (MyHC) expression to
analyze myotube formation in the three groups (Fig. 5A–C). To
FIG. 4. Marker profile analysis of MDSCs. (A) Flow cytometry revealed high expression levels of the stem cell markers CD34
and Sca-1 (70%) by the control cells (C-MDSCs) and 7 days after either retroviral transduction of the cells with the CL-NGF
vector (E-MDSCs) or stimulation with NGF (S-MDSCs). After 2 weeks of in vitro expansion, the groups exhibited no signifi-
cant differences in marker profiles (n  3, p  0.655). Data were collected by performing logarithmic amplification on 5000 cells
and excluding cell debris by combining forward and side scatters and are presented as dot plots (the percentage of cells in each
relevant quadrant is indicated in the upper right-hand corner). (B) A myogenic differentiation assay revealed low levels of Pax-
7 and desmin expression. There were no significant differences in Pax-7 expression between the treated groups and the control
and no significant difference in desmin expression between E-MDSCs and C-MDSCs; however, direct stimulation of MDSCs
with NGF resulted in significantly more desmin-positive cells in the S-MDSC group (n  4, *p  0.05).
determine the effect of cell confluency or cell differentiation, we
seeded the cells at a density of either 500 or 1000 cells/cm2 and
switched the cells to differentiation medium 3 days or 1 day af-
ter initial seeding. Under these experimental conditions, S-MD-
SCs consistently showed significantly lower rates of differentia-
tion efficiency than C- and E-MDSCs, which indicates that
S-MDSCs had a decreased ability to fuse and form multinucle-
ated myotubes (Fig. 5D–G: *p  0.05 [S-MDSCs versus C-MD-
SCs], 	p  0.05 [E-MDSCs versus C-MDSCs], and #p  0.05
[E-MDSCs versus S-MDSCs], Kruskal–Wallis one-way ANOVA
on ranks). The differentiation efficiency of the E-MDSCs appears
to lie between the values for C-MDSCs and S-MDSCs at all time
points in both experimental conditions. These results were con-
sistent regardless of initial cell seeding density or assay duration.
Each graph portrays results that are representative of three inde-
pendent experiments.
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FIG. 5. Time course of myogenic differentiation in vitro. Representative images of MyHC-positive C-, E-, and S-MDSCs (Cy3;
red) overlaid on nuclear counterstain (DAPI; blue) are shown (A–C). Scale bar: 100 m. The degree of differentiation (percent
ratio of MyoD- or MyHC-expressing nuclei to total nuclei) is indicated both for cells seeded at an initial density of 500 cells/cm2,
switched to differentiation medium after 3 days, and stained at 2, 4, 6, and 8 days for MyoD (D) and MyHC expression (E) and
for cells seeded at an initial density of 1000 cells/cm2, switched to differentiation medium the next day, and stained at 3, 5, 7,
9, and 11 days for MyoD (F) and MyHC expression (G). Comparison of E-MDSCs (solid squares) with C-MDSCs (solid cir-
cles) revealed that the differentiation efficiency of the E-MDSCs appears to lie between the values for C-MDSCs and S-MDSCs
at all time points under both experimental conditions; however, in comparison with C-MDSCs, S-MDSCs seeded at either den-
sity (solid triangles) consistently exhibited a lower degree of differentiation (*p  0.05 [S-MDSCs versus C-MDSCs], 	p  0.05
[E-MDSCs versus C-MDSCs], and #p  0.05 [E-MDSCs versus S-MDSCs], Kruskal–Wallis one-way ANOVA on ranks) (D–G).
Each graph portrays results that are representative of three independent experiments.
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FIG. 6. Dystrophin-positive myofiber regeneration elicited by
MDSCs transduced with CL-NGF. Cryosections of the gas-
trocnemius muscle of mdx mice immunostained for dystrophin
expression show grafts generated by the implanted E-MDSCs
(A) or C-MDSCs (B). Scale bar: 250 m. In comparison with
C-MDSC transplantation, E-MDSC transplantation signifi-
cantly improved the regeneration of dystrophic muscle, as in-
dicated by a significantly higher RI 14 days after injection.
(435.6  85.5 versus 197.5  53.8, n  8, *p  0.001) (C).
Muscle regeneration
We evaluated the ability of the three groups of cells (C-, E-,
and S-MDSCs) to regenerate dystrophic skeletal muscle by
transplanting 3  105 cells from each cell group into the gas-
trocnemius muscles of 8-week-old male mdx mice. The dys-
trophin-positive grafts of E- and C-MDSCs are shown in Fig.
6A and B. The average RI of E-MDSCs was significantly larger
than that of C-MDSCs (435.6  85.5 versus 197.5  53.8, n 
8 mice per group, p  0.001; Fig. 6C). Differences in the size
of the dystrophin-positive grafts generated by S-MDSCs and
C-MDSCs were even more dramatic, as shown in Fig. 7A and
B, respectively. Our analysis revealed that the average RI of S-
MDSCs was 3-fold higher than that of C-MDSCs (852  203.3
versus 266.8  137.4, n  11 mice per group, p  0.001; Fig.
7C). In addition, the RI of S-MDSCs was statistically higher
than that of E-MDSCs (p  0.001).
FAD analysis of grafts generated by the three groups of
MDSCs revealed that more than 50% of the dystrophin-posi-
tive myofibers (n  5000 myofibers) in each group had areas
of 0–100 m2; in this range, no statistically significant dif-
ferences existed among the treatment groups compared with
C-MDSCs (p  0.678; Fig. 8). We also analyzed noninjected
areas of mdx muscle and found that most of the myofibers had
areas greater than 1000 m2. These findings indicate that 
C-, E-, and S-MDSCs generated new dystrophin-positive my-
ofibers primarily through the fusion of donor cells with one an-
other, as indicated by the small size and centronucleation of the
regenerated myofibers (Fig. 8B).
DISCUSSION
Although the precise role that NGF plays in the various steps
of muscle regeneration remains largely unknown, our observa-
tions indicate that NGF can improve the ability of MDSCs to
regenerate the skeletal muscle of mdx mice. Whereas the re-
sults of our in vitro experiments demonstrate that neither retro-
NGF transduction nor direct stimulation with NGF protein
changes the marker profile of MDSCs or their proliferation dy-
namics, direct stimulation with NGF protein appears to reduce
the myogenic differentiation of MDSCs in vitro.
The process of muscle regeneration in normal and dystrophic
muscle depends on locally produced cytokines and growth fac-
tors (DiMario et al., 1989; Anderson et al., 1991; Clarke et al.,
1993; Trippel, 1997). Skeletal muscle injuries induce a well-
established sequence of cellular events that result in the release
of growth factors that stimulate quiescent satellite cells and
other muscle precursor cells to enter the cell cycle, proliferate,
and eventually fuse to form newly regenerated myofibers and
restore muscle architecture (White and Esser, 1989; Grounds,
1991). Some studies suggest that NGF, the best characterized
neurotrophic factor, plays an important role in restoring inner-
vation in many tissues after injury. For example, NGF is inte-
gral to the survival of sensory and peripheral neurons that con-
trol contraction of smooth muscle (Kushima et al., 1992;
Shitaka and Saito, 1994; Acosta et al., 2001) and axonal re-
generation in skeletal muscle (McCallister et al., 2001).
A prior study performed in our laboratory has shown that
MDSCs stimulated with NGF or vascular endothelial growth
factor (VEGF) acquire the expression of 2,3-cyclic nucleotide
3-phosphodiesterase (CNPase), a myelin-associated enzyme,
and von Willebrand factor (vWF), an endothelial cell marker
(Qu-Petersen et al., 2002), findings that indicate the potential
differentiation of MDSCs toward neurogenic and endothelial
lineages, respectively. These results suggest that the release of
local environmental cues (1) can trigger the differentiation of
muscle stem cells toward nonmyogenic lineages after trans-
plantation of the cells into dystrophic muscle and (2) may con-
tribute to the regeneration of functional muscle tissue by en-
hancing vascular and neuronal supplies.
Here we investigated whether MDSCs retrovirally trans-
duced to express NGF display different proliferation behavior
or altered myogenic differentiation in vitro and improved re-
generation of dystrophic muscle in vivo. We used MDSCs rather
than satellite cells because MDSCs exhibit a superior trans-
plantation capacity in skeletal muscle and the ability to undergo
multilineage differentiation (Jankowski et al., 2002; Qu-Petersen
et al., 2002). The ex vivo gene transfer approach enables con-
stant delivery of lower, more physiological doses of proteins
that, if delivered by direct injection, would be quickly degraded
by natural processes. Retroviral vectors infect dividing cells with
high efficiency (Salvatori et al., 1993) and elicit long-term, sta-
ble expression of the gene of interest by becoming integrated
within the host cell genome; such vectors are already being used
in clinical settings (Anderson, 1992; Miller et al., 1992). Our re-
sults indicate that MDSCs transduced with a retrovirus vector
continuously delivered high levels of NGF for up to 9 days in
culture while maintaining their typical stem cell marker profile
(CD34 positive and Sca-1 positive). After injection into the
skeletal muscle of mdx mice, E-MDSCs proliferated and differ-
entiated to generate dystrophin-positive muscle fibers that
formed a large graft as early as 14 days after injection.
The proliferation dynamics of the treated MDSCs, including
PDT, DT, and , were similar irrespective of the treatment method
(i.e., stimulation or transduction). However, S-MDSCs exhibited
higher regeneration efficiency in vivo than did E-MDSCs or 
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FIG. 7. Dystrophin-positive myofiber regeneration elicited
by MDSCs stimulated with NGF protein. Cryosections of the
gastrocnemius muscle immunostained for dystrophin expres-
sion show grafts generated by the implanted S-MDSCs (A)
or C-MDSCs (B). Scale bar: 250 m. In comparison with C-
MDSCs, S-MDSCs elicited the formation of significantly
larger grafts equivalent to a 3-fold increase in muscle regen-
eration 14 days after injection. The average RI of S-MDSCs
was significantly higher than that of C-MDSCs (852  203.3
versus 266.8  137.4, n  11, *p  0.001) (C).
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C-MDSCs. Our examination of NGF secretion by the S- and
E-MDSCs in vivo revealed no differences in the immunoreactiv-
ity of the cells to NGF (data not shown). However, it is impor-
tant to note that the immunopositivity exhibited by the MDSCs
could be due to both NGF from other sources in the muscle and
NGF secreted by the injected cells. We postulate that the en-
hanced muscle regeneration exhibited by S-MDSCs compared
with E- and C-MDSCs in vivo might be due to the lower de-
gree of S-MDSC differentiation. Some research suggests that
muscle cells with decreased fusion characteristics have in-
creased regeneration capacities in skeletal muscle (Jankowski
et al., 2002). This could explain our observation that S-MDSCs
differentiated into myotubes less effectively than did C- and E-
MDSCs in vitro and exhibited the greatest regeneration effi-
ciency in vivo. The higher proliferation ability of S-MDSCs be-
fore fusion in vivo might have allowed them to remain in an
undifferentiated state longer, which would result in enhanced
regeneration.
We were unable to uncover a cellular mechanism that would
explain the relationship between the lower expression of the myo-
genic differentiation markers MyoD and MyHC by S-MDSCs and
their higher expression of the myogenic proliferation marker
desmin. We posit that exposure to exogenous NGF myogenic
differentiation conditions (low serum level) reduces differenti-
ation but permits proliferation. S-MDSCs and E-MDSCs ini-
tially seeded at higher densities and switched to differentiation
medium 3 days after seeding showed lower fusion kinetics in
vitro than did similarly cultured C-MDSCs.
Reddypalli and associates (2005) reported that signaling me-
diated by p75NTR, the low-affinity receptor for NGF, plays an
important role in normal muscle development; indeed, the ab-
sence of p75NTR in mutant mice leads to impaired muscle force.
They have also found that p75NTR -mediated phosphorylation
of Akt plays an important role in myoblast survival and that en-
dogenous activation of Akt is most likely mediated by secreted
NGF. The significance of the autocrine signaling by NGF is
underscored by its downregulation before myoblast differenti-
ation (Rende et al., 2000). Because Akt mediates cell survival
and p75NTR activation can promote phosphorylation of Akt, we
posit that NGF activates Akt through p75NTR in MDSCs and
thus promotes the survival of the MDSCs and their transition
into differentiated states. On the basis of these findings, we be-
lieve that stimulated MDSC expression of NGF at optimal lev-
els (i.e., levels that closely mimic biologic conditions) leads to
endogenous activation of Akt and subsequent autocrine signal-
ing of NGF. Consequently, high levels of NGF expression (as
exhibited by E-MDSCs) likely reflect changes such as down-
regulation of p75NTR and/or the TrkA receptor for NGF that re-
duce overall binding affinities for NGF. The results of future
experiments should facilitate elucidation of the signaling mech-
anisms and the link between the in vitro and in vivo settings
used to study muscle regeneration.
The FAD shows that most of the individual dystrophin-posi-
tive myofibers in all the MDSC groups had areas of 0–100 m2,
whereas most of the host mdx myofibers had areas of 1000 m2.
Nuclear staining with DAPI revealed that most of the small my-
ofibers observed in the MDSC grafts were centronucleated. In
combination, these results suggest that injection of C-, E-, or S-
MDSCs led to the formation of new dystrophin-positive myofibers
via the fusion of donor cells with one another rather than the fu-
sion of donor cells with host muscle fibers. Studies conducted by
Toti and associates (2003) show that only regenerated myofibers
FIG. 8. Fiber area distribution (FAD) of newly generated (dystrophin-positive) and host myofibers. The overall distribution
shows that most dystrophin-positive myofibers observed in the MDSC groups had areas of 0–100 m2, whereas most host mdx
myofibers (control) had areas greater than 1000 m2 (A). In addition, a high-magnification image of a small portion of an E-
MDSC graft, which is representative of the grafts observed in all MDSC groups, shows a large number of dystrophin-positive
centronucleated myofibers (B). Five thousand myofibers in treated (dystrophin-positive) and noninjected areas were analyzed in
each group.
in the muscles of DMD patients consistently express NGF; dys-
trophic myofibers or healthy myofibers do not show NGF im-
munoreactivity. In addition, the authors report that regenerated
myofibers in muscle biopsy specimens from DMD patients are
small and round, and occur mostly in clusters. These observations
led them to hypothesize that, in addition to its autocrine function,
NGF has a paracrine effect on neighboring regenerated myofibers.
Our observations of myofibers generated by the MDSCs trans-
planted into the skeletal muscle of mdx mice in this study, par-
ticularly E-MDSCs, suggest a similar phenomenon.
Our study results show that NGF plays an important role in
enhancing muscle regeneration by MDSCs. The performance
of additional research focused on NGF will substantially en-
hance our understanding of the mechanism underlying this ef-
fect and, in so doing, may lead to the improvement of cell and
gene therapy strategies for the treatment of DMD and other
muscular dystrophies.
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